| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
| Arthritis, Juvenile | 22 | 2020 | 191 | 6.69 | Why? |
| Mucocutaneous Lymph Node Syndrome | 13 | 2021 | 1645 | 2.12 | Why? |
| Uveitis | 5 | 2020 | 233 | 2.07 | Why? |
| Antirheumatic Agents | 15 | 2021 | 3023 | 1.96 | Why? |
| Biological Products | 6 | 2020 | 2331 | 1.20 | Why? |
| Bone Density Conservation Agents | 2 | 2017 | 209 | 1.14 | Why? |
| Arthritis | 4 | 2020 | 288 | 1.01 | Why? |
| Coronary Aneurysm | 4 | 2020 | 132 | 0.93 | Why? |
| Osteoporosis | 2 | 2017 | 410 | 0.90 | Why? |
| Adalimumab | 3 | 2019 | 389 | 0.85 | Why? |
| Rheumatic Diseases | 6 | 2020 | 2675 | 0.85 | Why? |
| Hereditary Autoinflammatory Diseases | 2 | 2019 | 72 | 0.82 | Why? |
| Systemic Vasculitis | 1 | 2020 | 74 | 0.78 | Why? |
| Child | 51 | 2021 | 70012 | 0.77 | Why? |
| Behcet Syndrome | 2 | 2017 | 136 | 0.73 | Why? |
| Body Height | 1 | 2018 | 100 | 0.70 | Why? |
| Teratoma | 1 | 2017 | 25 | 0.70 | Why? |
| Synovial Membrane | 2 | 2018 | 72 | 0.69 | Why? |
| Joint Instability | 1 | 2017 | 20 | 0.69 | Why? |
| Carbonic Anhydrase IX | 1 | 2016 | 11 | 0.67 | Why? |
| Carbonic Anhydrases | 1 | 2016 | 13 | 0.66 | Why? |
| Dapsone | 1 | 2017 | 59 | 0.66 | Why? |
| Rheumatologists | 2 | 2020 | 346 | 0.65 | Why? |
| Rheumatology | 4 | 2020 | 1213 | 0.64 | Why? |
| Anti-N-Methyl-D-Aspartate Receptor Encephalitis | 1 | 2017 | 82 | 0.63 | Why? |
| Arthritis, Infectious | 1 | 2017 | 111 | 0.61 | Why? |
| Arthralgia | 1 | 2017 | 173 | 0.61 | Why? |
| Immunoglobulins, Intravenous | 6 | 2021 | 2705 | 0.61 | Why? |
| Immunologic Factors | 5 | 2021 | 4206 | 0.60 | Why? |
| Pemphigoid, Bullous | 1 | 2017 | 89 | 0.60 | Why? |
| Bone Density | 2 | 2017 | 335 | 0.59 | Why? |
| Osteomyelitis | 1 | 2017 | 131 | 0.59 | Why? |
| Musculoskeletal Pain | 1 | 2017 | 108 | 0.58 | Why? |
| Pediatricians | 1 | 2020 | 401 | 0.58 | Why? |
| Withholding Treatment | 2 | 2018 | 798 | 0.57 | Why? |
| Child Development | 1 | 2018 | 352 | 0.54 | Why? |
| Drugs, Investigational | 1 | 2017 | 198 | 0.54 | Why? |
| Interleukin-1beta | 3 | 2019 | 992 | 0.52 | Why? |
| Systemic Inflammatory Response Syndrome | 4 | 2021 | 6653 | 0.52 | Why? |
| Aspirin | 3 | 2021 | 1043 | 0.50 | Why? |
| Interleukin 1 Receptor Antagonist Protein | 7 | 2021 | 1165 | 0.50 | Why? |
| Disease Management | 4 | 2020 | 6841 | 0.50 | Why? |
| Physical Examination | 2 | 2018 | 755 | 0.48 | Why? |
| Ovarian Neoplasms | 1 | 2017 | 465 | 0.45 | Why? |
| Fractures, Bone | 1 | 2017 | 487 | 0.44 | Why? |
| Anti-Inflammatory Agents | 4 | 2019 | 6153 | 0.44 | Why? |
| Lupus Erythematosus, Systemic | 3 | 2019 | 1380 | 0.42 | Why? |
| Child, Preschool | 22 | 2021 | 36283 | 0.39 | Why? |
| Th17 Cells | 3 | 2019 | 657 | 0.37 | Why? |
| Fever | 4 | 2020 | 7795 | 0.37 | Why? |
| Forkhead Transcription Factors | 1 | 2010 | 231 | 0.37 | Why? |
| Exercise Therapy | 1 | 2017 | 976 | 0.36 | Why? |
| Pain Management | 1 | 2017 | 854 | 0.36 | Why? |
| Fibrinolytic Agents | 1 | 2020 | 1702 | 0.35 | Why? |
| Th1 Cells | 3 | 2019 | 1228 | 0.35 | Why? |
| Synovitis | 2 | 2018 | 47 | 0.34 | Why? |
| Familial Mediterranean Fever | 2 | 2019 | 88 | 0.34 | Why? |
| Glucocorticoids | 4 | 2021 | 4431 | 0.33 | Why? |
| Remission Induction | 4 | 2018 | 950 | 0.33 | Why? |
| Methotrexate | 4 | 2018 | 471 | 0.33 | Why? |
| Autoimmune Diseases | 2 | 2018 | 1996 | 0.32 | Why? |
| Methylprednisolone | 1 | 2017 | 2107 | 0.31 | Why? |
| Italy | 14 | 2021 | 38444 | 0.31 | Why? |
| Antibodies, Monoclonal | 4 | 2019 | 8041 | 0.31 | Why? |
| Body Mass Index | 1 | 2018 | 4306 | 0.29 | Why? |
| Recurrence | 5 | 2018 | 3675 | 0.29 | Why? |
| Infant | 14 | 2021 | 30274 | 0.28 | Why? |
| Antimalarials | 1 | 2017 | 2505 | 0.28 | Why? |
| Adolescent | 21 | 2020 | 86841 | 0.28 | Why? |
| Diagnosis, Differential | 5 | 2020 | 7220 | 0.27 | Why? |
| Referral and Consultation | 1 | 2020 | 4816 | 0.27 | Why? |
| Polymorphism, Genetic | 3 | 2020 | 1074 | 0.26 | Why? |
| Immunotherapy | 1 | 2017 | 2421 | 0.26 | Why? |
| Alendronate | 1 | 2002 | 12 | 0.25 | Why? |
| Receptors, Tumor Necrosis Factor, Type I | 2 | 2017 | 229 | 0.25 | Why? |
| Nuclear Receptor Subfamily 1, Group F, Member 3 | 2 | 2018 | 24 | 0.24 | Why? |
| Bone Resorption | 1 | 2002 | 61 | 0.24 | Why? |
| Humans | 70 | 2021 | 930598 | 0.24 | Why? |
| Siblings | 2 | 2019 | 226 | 0.21 | Why? |
| Adrenal Cortex Hormones | 2 | 2017 | 6537 | 0.21 | Why? |
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2020 | 1454 | 0.21 | Why? |
| Receptors, Interleukin-1 | 2 | 2019 | 161 | 0.21 | Why? |
| Parvovirus | 1 | 2019 | 20 | 0.20 | Why? |
| Mevalonate Kinase Deficiency | 1 | 2019 | 10 | 0.20 | Why? |
| Dermatomyositis | 2 | 2017 | 193 | 0.20 | Why? |
| Cryopyrin-Associated Periodic Syndromes | 1 | 2019 | 20 | 0.20 | Why? |
| Nephritis | 1 | 2019 | 39 | 0.19 | Why? |
| Primary Health Care | 1 | 2017 | 4839 | 0.19 | Why? |
| T-Box Domain Proteins | 1 | 2018 | 62 | 0.19 | Why? |
| Ficusin | 1 | 2018 | 5 | 0.19 | Why? |
| Scleroderma, Localized | 1 | 2018 | 25 | 0.18 | Why? |
| Pyrin | 1 | 2018 | 15 | 0.18 | Why? |
| Sweating | 1 | 2017 | 52 | 0.18 | Why? |
| Antibodies, Anti-Idiotypic | 1 | 2018 | 93 | 0.18 | Why? |
| Receptors, Glucocorticoid | 1 | 2019 | 118 | 0.18 | Why? |
| Polymorphism, Single Nucleotide | 2 | 2017 | 3607 | 0.17 | Why? |
| CARD Signaling Adaptor Proteins | 1 | 2018 | 70 | 0.17 | Why? |
| STAT5 Transcription Factor | 1 | 2017 | 34 | 0.17 | Why? |
| Adenosine Deaminase | 1 | 2018 | 85 | 0.17 | Why? |
| Hormone Replacement Therapy | 1 | 2019 | 146 | 0.17 | Why? |
| Sarcoidosis | 2 | 2018 | 271 | 0.17 | Why? |
| Hip Joint | 1 | 2017 | 59 | 0.17 | Why? |
| Treatment Outcome | 11 | 2019 | 51732 | 0.17 | Why? |
| Heart Block | 1 | 2017 | 59 | 0.17 | Why? |
| Hypotension | 1 | 2021 | 392 | 0.17 | Why? |
| Arthritis, Rheumatoid | 3 | 2020 | 2043 | 0.17 | Why? |
| Tumor Necrosis Factor-alpha | 3 | 2019 | 2483 | 0.17 | Why? |
| Severe Combined Immunodeficiency | 1 | 2018 | 107 | 0.17 | Why? |
| Calcium-Binding Proteins | 1 | 2018 | 121 | 0.17 | Why? |
| Parvoviridae Infections | 1 | 2019 | 222 | 0.17 | Why? |
| Absorptiometry, Photon | 1 | 2017 | 168 | 0.16 | Why? |
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 96 | 0.16 | Why? |
| Ultraviolet Therapy | 1 | 2018 | 138 | 0.16 | Why? |
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 245 | 0.16 | Why? |
| HLA-C Antigens | 1 | 2017 | 195 | 0.15 | Why? |
| Delayed Diagnosis | 3 | 2020 | 1529 | 0.15 | Why? |
| Agammaglobulinemia | 1 | 2018 | 213 | 0.15 | Why? |
| Photosensitizing Agents | 1 | 2018 | 279 | 0.15 | Why? |
| Shock | 2 | 2021 | 1868 | 0.14 | Why? |
| Clinical Trials as Topic | 3 | 2020 | 7330 | 0.14 | Why? |
| Interferon-gamma Release Tests | 1 | 2017 | 253 | 0.14 | Why? |
| Terminology as Topic | 1 | 2020 | 546 | 0.14 | Why? |
| Female | 30 | 2021 | 380317 | 0.14 | Why? |
| Ultrasonography, Doppler | 1 | 2018 | 406 | 0.14 | Why? |
| Disability Evaluation | 1 | 2018 | 671 | 0.14 | Why? |
| Biological Factors | 1 | 2017 | 276 | 0.14 | Why? |
| Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis | 1 | 2017 | 235 | 0.13 | Why? |
| Incidence | 4 | 2020 | 25622 | 0.13 | Why? |
| Antibodies, Monoclonal, Humanized | 5 | 2019 | 9335 | 0.13 | Why? |
| Risk Assessment | 1 | 2017 | 25439 | 0.13 | Why? |
| Serum Amyloid A Protein | 1 | 2014 | 211 | 0.12 | Why? |
| Photochemotherapy | 1 | 2018 | 297 | 0.12 | Why? |
| Genetic Predisposition to Disease | 3 | 2019 | 4027 | 0.12 | Why? |
| NLR Family, Pyrin Domain-Containing 3 Protein | 1 | 2018 | 581 | 0.12 | Why? |
| Patient Reported Outcome Measures | 1 | 2018 | 912 | 0.12 | Why? |
| Antibodies | 1 | 2018 | 846 | 0.12 | Why? |
| Male | 25 | 2021 | 367725 | 0.12 | Why? |
| Dermatologic Agents | 1 | 2018 | 489 | 0.11 | Why? |
| Weight Loss | 1 | 2017 | 826 | 0.11 | Why? |
| Inflammation | 3 | 2019 | 13255 | 0.11 | Why? |
| Infant, Newborn | 5 | 2020 | 23105 | 0.11 | Why? |
| Peptide Hydrolases | 1 | 2019 | 1269 | 0.11 | Why? |
| Interleukin-1 | 1 | 2015 | 438 | 0.11 | Why? |
| Cooperative Behavior | 1 | 2019 | 1216 | 0.11 | Why? |
| Molecular Structure | 1 | 2016 | 1539 | 0.11 | Why? |
| T-Lymphocyte Subsets | 1 | 2018 | 1387 | 0.11 | Why? |
| Early Diagnosis | 1 | 2020 | 2443 | 0.11 | Why? |
| Pneumonia, Viral | 6 | 2020 | 243684 | 0.11 | Why? |
| Coronavirus Infections | 6 | 2020 | 253789 | 0.10 | Why? |
| Predictive Value of Tests | 4 | 2018 | 9537 | 0.10 | Why? |
| Interleukin-6 | 2 | 2020 | 7522 | 0.10 | Why? |
| Retrospective Studies | 8 | 2021 | 105322 | 0.10 | Why? |
| Cell Plasticity | 2 | 2019 | 75 | 0.09 | Why? |
| Evidence-Based Medicine | 2 | 2019 | 3228 | 0.09 | Why? |
| Lymphopenia | 1 | 2021 | 2669 | 0.09 | Why? |
| Mutation | 4 | 2018 | 12376 | 0.09 | Why? |
| Drug Approval | 1 | 2017 | 1325 | 0.09 | Why? |
| Precision Medicine | 1 | 2018 | 1477 | 0.09 | Why? |
| Immunosuppressive Agents | 4 | 2019 | 6331 | 0.08 | Why? |
| Age Factors | 2 | 2019 | 21039 | 0.08 | Why? |
| Betacoronavirus | 6 | 2020 | 204454 | 0.08 | Why? |
| Family | 1 | 2020 | 2909 | 0.08 | Why? |
| Coronary Artery Disease | 1 | 2021 | 2570 | 0.08 | Why? |
| Monocytes | 1 | 2018 | 2978 | 0.07 | Why? |
| Chloroquine | 1 | 2020 | 3152 | 0.07 | Why? |
| Myocarditis | 1 | 2021 | 2731 | 0.07 | Why? |
| Pericarditis | 1 | 2010 | 417 | 0.07 | Why? |
| Time Factors | 2 | 2018 | 31397 | 0.07 | Why? |
| Drug Design | 1 | 2017 | 2627 | 0.07 | Why? |
| Kidney | 1 | 2019 | 3648 | 0.07 | Why? |
| Magnetic Resonance Imaging | 2 | 2018 | 6551 | 0.07 | Why? |
| Pandemics | 8 | 2020 | 389249 | 0.06 | Why? |
| Liver | 1 | 2018 | 4007 | 0.06 | Why? |
| Health Promotion | 1 | 2017 | 2020 | 0.06 | Why? |
| Public Health Surveillance | 1 | 2017 | 3129 | 0.06 | Why? |
| T-Lymphocytes, Regulatory | 1 | 2010 | 698 | 0.06 | Why? |
| Immunocompromised Host | 1 | 2020 | 5150 | 0.06 | Why? |
| Genotype | 2 | 2017 | 4697 | 0.06 | Why? |
| Liver Diseases | 1 | 2018 | 2698 | 0.06 | Why? |
| Chronic Disease | 1 | 2017 | 5139 | 0.06 | Why? |
| Longitudinal Studies | 1 | 2017 | 9893 | 0.06 | Why? |
| Databases, Factual | 1 | 2017 | 6248 | 0.06 | Why? |
| Anthropometry | 1 | 2002 | 233 | 0.06 | Why? |
| Flow Cytometry | 1 | 2010 | 2393 | 0.05 | Why? |
| Adult | 11 | 2020 | 244371 | 0.05 | Why? |
| Lumbar Vertebrae | 1 | 2002 | 196 | 0.05 | Why? |
| Tachypnea | 1 | 2021 | 197 | 0.05 | Why? |
| Dobutamine | 1 | 2019 | 36 | 0.05 | Why? |
| Cartilage, Articular | 1 | 2019 | 50 | 0.05 | Why? |
| Spondylarthropathies | 1 | 2020 | 163 | 0.05 | Why? |
| Nigericin | 1 | 2018 | 5 | 0.05 | Why? |
| Synovial Fluid | 1 | 2019 | 64 | 0.05 | Why? |
| Dopamine | 1 | 2019 | 123 | 0.05 | Why? |
| rho GTP-Binding Proteins | 1 | 2018 | 18 | 0.05 | Why? |
| Practice Patterns, Physicians' | 1 | 2017 | 4927 | 0.05 | Why? |
| Protein Phosphatase 2 | 1 | 2017 | 18 | 0.04 | Why? |
| Choroiditis | 1 | 2017 | 18 | 0.04 | Why? |
| Translating | 1 | 2018 | 80 | 0.04 | Why? |
| Ionophores | 1 | 2018 | 60 | 0.04 | Why? |
| Salmonella typhimurium | 1 | 2018 | 81 | 0.04 | Why? |
| Interferon-gamma | 2 | 2018 | 2711 | 0.04 | Why? |
| Registries | 1 | 2017 | 12327 | 0.04 | Why? |
| Severity of Illness Index | 4 | 2020 | 48226 | 0.04 | Why? |
| Blood Sedimentation | 2 | 2014 | 508 | 0.04 | Why? |
| Cohort Studies | 2 | 2019 | 36005 | 0.04 | Why? |
| Phenotype | 2 | 2019 | 4037 | 0.04 | Why? |
| Genes, Reporter | 1 | 2018 | 472 | 0.04 | Why? |
| Cultural Characteristics | 1 | 2018 | 159 | 0.04 | Why? |
| Exercise | 1 | 2017 | 6771 | 0.04 | Why? |
| Bone and Bones | 1 | 2019 | 235 | 0.04 | Why? |
| Global Health | 2 | 2017 | 13911 | 0.04 | Why? |
| Acute Disease | 1 | 2010 | 6029 | 0.04 | Why? |
| Cells, Cultured | 2 | 2018 | 5835 | 0.04 | Why? |
| Fathers | 1 | 2017 | 114 | 0.04 | Why? |
| Surface Plasmon Resonance | 1 | 2018 | 440 | 0.04 | Why? |
| Tuberculin Test | 1 | 2017 | 141 | 0.04 | Why? |
| Pedigree | 1 | 2017 | 502 | 0.04 | Why? |
| Bacterial Toxins | 1 | 2018 | 185 | 0.04 | Why? |
| Hydroxychloroquine | 1 | 2020 | 12447 | 0.04 | Why? |
| Age of Onset | 1 | 2018 | 557 | 0.04 | Why? |
| Cardiotonic Agents | 1 | 2019 | 418 | 0.04 | Why? |
| Cross-Sectional Studies | 3 | 2018 | 53120 | 0.04 | Why? |
| Vomiting | 1 | 2021 | 722 | 0.04 | Why? |
| DNA Mutational Analysis | 1 | 2018 | 581 | 0.04 | Why? |
| Antibodies, Antinuclear | 1 | 2017 | 234 | 0.04 | Why? |
| Interleukin-18 | 1 | 2018 | 328 | 0.04 | Why? |
| Animals | 4 | 2019 | 78931 | 0.04 | Why? |
| STAT3 Transcription Factor | 1 | 2017 | 268 | 0.04 | Why? |
| Troponin T | 1 | 2021 | 771 | 0.04 | Why? |
| Cell Death | 1 | 2018 | 536 | 0.04 | Why? |
| RNA, Messenger | 1 | 2010 | 5131 | 0.04 | Why? |
| Interleukin-2 | 1 | 2017 | 443 | 0.04 | Why? |
| Adenosine Triphosphate | 1 | 2018 | 294 | 0.04 | Why? |
| Conjunctivitis | 1 | 2019 | 318 | 0.04 | Why? |
| Nerve Tissue Proteins | 1 | 2017 | 319 | 0.04 | Why? |
| Antigens, Bacterial | 1 | 2018 | 330 | 0.04 | Why? |
| Follow-Up Studies | 3 | 2018 | 17020 | 0.03 | Why? |
| Case-Control Studies | 3 | 2018 | 17671 | 0.03 | Why? |
| Health Knowledge, Attitudes, Practice | 1 | 2017 | 8811 | 0.03 | Why? |
| Janus Kinase Inhibitors | 1 | 2020 | 682 | 0.03 | Why? |
| Disease Progression | 3 | 2018 | 13580 | 0.03 | Why? |
| Radiography | 1 | 2002 | 1576 | 0.03 | Why? |
| Rare Diseases | 1 | 2018 | 373 | 0.03 | Why? |
| Symptom Flare Up | 1 | 2018 | 432 | 0.03 | Why? |
| Intensive Care Units, Pediatric | 1 | 2021 | 1098 | 0.03 | Why? |
| Interleukin-17 | 1 | 2018 | 602 | 0.03 | Why? |
| Arthritis, Psoriatic | 1 | 2020 | 625 | 0.03 | Why? |
| Phosphorylation | 1 | 2017 | 1060 | 0.03 | Why? |
| Mice, Knockout | 1 | 2018 | 1815 | 0.03 | Why? |
| Lymphadenopathy | 1 | 2019 | 444 | 0.03 | Why? |
| Pediatrics | 2 | 2020 | 2969 | 0.03 | Why? |
| Macrophage Activation | 1 | 2015 | 315 | 0.03 | Why? |
| Consensus | 2 | 2018 | 6345 | 0.03 | Why? |
| Logistic Models | 2 | 2018 | 9089 | 0.03 | Why? |
| Latent Tuberculosis | 1 | 2017 | 324 | 0.03 | Why? |
| Enzyme-Linked Immunosorbent Assay | 2 | 2018 | 7868 | 0.03 | Why? |
| Cell Differentiation | 1 | 2018 | 1338 | 0.03 | Why? |
| Healthy Volunteers | 1 | 2018 | 1444 | 0.03 | Why? |
| Age Distribution | 1 | 2021 | 3567 | 0.03 | Why? |
| Visual Acuity | 1 | 2017 | 790 | 0.03 | Why? |
| Inflammasomes | 1 | 2018 | 710 | 0.03 | Why? |
| Risk Factors | 2 | 2017 | 71621 | 0.03 | Why? |
| Psychometrics | 1 | 2018 | 1269 | 0.03 | Why? |
| Advisory Committees | 1 | 2018 | 1418 | 0.03 | Why? |
| Drug Substitution | 1 | 2014 | 385 | 0.03 | Why? |
| Platelet Aggregation Inhibitors | 1 | 2021 | 1671 | 0.03 | Why? |
| Patients | 1 | 2018 | 1167 | 0.03 | Why? |
| Hospitalization | 2 | 2020 | 54280 | 0.02 | Why? |
| Exanthema | 1 | 2019 | 1097 | 0.02 | Why? |
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2010 | 13720 | 0.02 | Why? |
| Up-Regulation | 1 | 2017 | 2249 | 0.02 | Why? |
| Biopsy | 1 | 2018 | 2811 | 0.02 | Why? |
| Stroke Volume | 1 | 2019 | 2153 | 0.02 | Why? |
| Bacterial Proteins | 1 | 2018 | 1318 | 0.02 | Why? |
| Diarrhea | 1 | 2021 | 2743 | 0.02 | Why? |
| Combined Modality Therapy | 1 | 2018 | 3395 | 0.02 | Why? |
| C-Reactive Protein | 2 | 2021 | 7972 | 0.02 | Why? |
| Dyspnea | 1 | 2021 | 3847 | 0.02 | Why? |
| Prednisolone | 1 | 2010 | 443 | 0.02 | Why? |
| Cough | 1 | 2021 | 4891 | 0.02 | Why? |
| Mothers | 1 | 2017 | 1624 | 0.02 | Why? |
| Health Surveys | 1 | 2017 | 2841 | 0.02 | Why? |
| Odds Ratio | 1 | 2017 | 5861 | 0.02 | Why? |
| Biomarkers | 2 | 2014 | 23361 | 0.02 | Why? |
| Middle Aged | 6 | 2020 | 270681 | 0.02 | Why? |
| Antihypertensive Agents | 1 | 2017 | 1962 | 0.02 | Why? |
| Echocardiography | 1 | 2019 | 3661 | 0.02 | Why? |
| Cardiology | 1 | 2020 | 2873 | 0.02 | Why? |
| Prognosis | 2 | 2018 | 32490 | 0.02 | Why? |
| Health Status | 1 | 2018 | 3259 | 0.02 | Why? |
| Guidelines as Topic | 1 | 2017 | 2844 | 0.02 | Why? |
| Parents | 1 | 2018 | 2758 | 0.02 | Why? |
| Prospective Studies | 2 | 2018 | 43301 | 0.01 | Why? |
| Heart Diseases | 1 | 2019 | 3503 | 0.01 | Why? |
| Reproducibility of Results | 1 | 2018 | 11304 | 0.01 | Why? |
| Patient Acceptance of Health Care | 1 | 2020 | 5002 | 0.01 | Why? |
| Tuberculosis | 1 | 2017 | 2895 | 0.01 | Why? |
| Europe | 1 | 2017 | 12702 | 0.01 | Why? |
| Protein Binding | 1 | 2017 | 11430 | 0.01 | Why? |
| Sex Factors | 1 | 2017 | 11014 | 0.01 | Why? |
| Heart Failure | 1 | 2021 | 6638 | 0.01 | Why? |
| India | 1 | 2017 | 11875 | 0.01 | Why? |
| Mice | 1 | 2018 | 21357 | 0.01 | Why? |
| Randomized Controlled Trials as Topic | 1 | 2017 | 10649 | 0.01 | Why? |
| Mass Screening | 1 | 2017 | 8005 | 0.01 | Why? |
| Quality of Life | 1 | 2018 | 9820 | 0.01 | Why? |
| Immunity, Innate | 1 | 2015 | 6570 | 0.01 | Why? |
| Drug Therapy, Combination | 1 | 2010 | 7268 | 0.01 | Why? |
| Health Services Accessibility | 1 | 2020 | 10697 | 0.01 | Why? |
| Hemoglobins | 1 | 2002 | 958 | 0.01 | Why? |
| Sensitivity and Specificity | 1 | 2017 | 22971 | 0.01 | Why? |
| Practice Guidelines as Topic | 1 | 2018 | 15421 | 0.01 | Why? |
| China | 1 | 2020 | 50654 | 0.01 | Why? |
| United States | 1 | 2017 | 46150 | 0.01 | Why? |
| Young Adult | 1 | 2018 | 93724 | 0.01 | Why? |
| Aged | 1 | 2020 | 215776 | 0.00 | Why? |
| Prevalence | 1 | 2002 | 25773 | 0.00 | Why? |